HC Wainwright reissued their buy rating on shares of TransCode Therapeutics (NASDAQ:RNAZ – Free Report) in a research note published on Thursday, Benzinga reports. The brokerage currently has a $3.00 target price on the stock.
TransCode Therapeutics Stock Performance
NASDAQ RNAZ traded down $0.01 during mid-day trading on Thursday, hitting $0.64. The stock had a trading volume of 6,042 shares, compared to its average volume of 1,304,766. The company has a 50 day simple moving average of $0.43 and a 200 day simple moving average of $0.70. TransCode Therapeutics has a 52-week low of $0.22 and a 52-week high of $19.42.
TransCode Therapeutics (NASDAQ:RNAZ – Get Free Report) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.16). Sell-side analysts expect that TransCode Therapeutics will post -2.06 EPS for the current fiscal year.
Institutional Trading of TransCode Therapeutics
TransCode Therapeutics Company Profile
TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.
Featured Stories
- Five stocks we like better than TransCode Therapeutics
- Why Invest in High-Yield Dividend Stocks?
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- What is a Dividend King?
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- The Downtrend in UPS Stock Isn’t Over Yet
Receive News & Ratings for TransCode Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransCode Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.